Emicizumab for acquired haemophilia A: A case series

Emicizumab is approved to prevent bleeding in patients with congenital haemophilia A with or without inhibitors. However, no randomized trials addressed the efficacy of emicizumab in acquired haemophilia A (AHA).

[1]  K. Yoneyama,et al.  A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. , 2022, Journal of thrombosis and haemostasis : JTH.

[2]  R. Handin,et al.  Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single‐institution experience , 2022, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  C. Kessler,et al.  Emicizumab for the Treatment of Acquired Hemophilia a: A Multicenter US Case Series , 2021, Blood.

[4]  C. Hermans,et al.  Emicizumab in acquired haemophilia A: about two clinical cases and literature review , 2021, Therapeutic advances in hematology.

[5]  N. Key,et al.  Emicizumab reduces re‐hospitalization for bleeding in acquired haemophilia A , 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  N. Key,et al.  Recombinant porcine FVIII for bleed treatment in acquired hemophilia A: findings from a single-center, 18-patient cohort. , 2020, Blood advances.

[7]  C. Négrier,et al.  Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study , 2020, Thrombosis and Haemostasis.

[8]  P. Giangrande,et al.  International recommendations on the diagnosis and treatment of acquired hemophilia A , 2020, Haematologica.

[9]  J. Mahlangu.  Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors , 2018, BioDrugs.

[10]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors , 2018, The New England journal of medicine.

[11]  J. Oldenburg,et al.  Emicizumab Prophylaxis in Hemophilia A with Inhibitors , 2017, The New England journal of medicine.

[12]  E. Gomperts,et al.  Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[13]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[14]  A. Giles,et al.  A 4% Solution of Bovine Serum Albumin May Be Used in Place of Factor VIII:C Deficient Plasma in the Control Sample in the Nijmegen Modification of the Bethesda Factor VIII:C Inhibitor Assay , 2002, Thrombosis and Haemostasis.